Equity Overview
Price & Market Data
Price: $6.30
Daily Change: +$0.36 / 5.71%
Daily Range: $6.21 - $6.30
Market Cap: $69,073,960
Daily Volume: 1,356
Performance Metrics
1 Week: 1.71%
1 Month: -7.62%
3 Months: 25.05%
6 Months: 42.11%
1 Year: 58.82%
YTD: 36.87%
Company Details
Employees: 14
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.